𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

✍ Scribed by Long, Georgina V.; Stroyakovskiy, Daniil; Gogas, Helen; Levchenko, Evgeny; de Braud, Filippo; Larkin, James; Garbe, Claus; Jouary, Thomas; Hauschild, Axel; Grob, Jean Jacques; Chiarion Sileni, Vanna; Lebbe, Celeste; Mandalà, Mario; Millward, Michael; Arance, Ana; Bondarenko, Igor; Haanen, John B.A.G.; Hansson, Johan; Utikal, Jochen; Ferraresi, Virginia; Kovalenko, Nadezhda; Mohr, Peter; Probachai, Volodymyr; Schadendorf, Dirk; Nathan, Paul; Robert, Caroline; Ribas, Antoni; DeMarini, Douglas J.; Irani, Jhangir G.; Casey, Michelle; Ouellet, Daniele; Martin, Anne-Marie; Le, Ngocdiep; Patel, Kiran; Flaherty, Keith

Book ID
126767995
Publisher
Massachusetts Medical Society
Year
2014
Tongue
English
Weight
570 KB
Volume
371
Category
Article
ISSN
0096-6762

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combined BRAF and MEK Inhibition in Mela
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
✍ Flaherty, Keith T.; Infante, Jeffery R.; Daud, Adil; Gonzalez, Rene; Kefford, Ri 📂 Article 📅 2012 🏛 Massachusetts Medical Society 🌐 English ⚖ 528 KB

## Background Resistance to therapy with BRAF kinase inhibitors is associated with reactivation of the mitogen-activated protein kinase (MAPK) pathway. To address this problem, we conducted a phase 1 and 2 trial of combined treatment with da braf e nib, a selective BRAF inhibitor, and trametinib, a